Skip to main content

Table 3 Results of simulations

From: A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method

Design

toxicity

patients

DLTs

study length (1.0/wk)

number skipped (1.0/wk)

study length (1.5/wk)

number skipped (1.5/wk)

MTD

STARPAC

T1

12.2

(12.2, 12.7)

3.28

(3.20, 3.54)

15.8

(15.8, 16.1)

3.47

(3.47, 3.76)

13.2

(13.0, 13.6)

7.32

(7.32, 7.67)

0.342

(0.317, 0.363)

TITE-CRM

T1

14.5

(14.5, 15.3)

4.23

(4.23, 4.66)

19.1

(19.1, 19.9)

4.27

(4.27, 4.57)

16.2

(15.9, 16.3)

9.07

(9.07, 9.41)

0.217

(0.162, 0.217)

3 + 3

T1

10.2

(10.1, 10.4)

2.64

(2.62, 2.71)

20.9

(20.9, 22.2)

9.90

(9.90, 10.28)

17.9

(17.9, 19.0)

14.44

(14.41, 14.95)

0.234

(0.234, 0.260)

STARPAC

T2

12.5

(12.4, 13.2)

3.01

(2.97, 3.30)

16.2

(16.2, 16.5)

3.70

(3.67, 3.75)

13.2

(13.2, 14.1)

7.57

(7.50, 8.09)

0.163

(0.117, 0.174)

TITE-CRM

T2

14.0

(13.8, 14.3)

3.66

(3.59, 3.81)

18.3

(17.9, 18.3)

4.15

(4.04, 4.15)

15.4

(14.9, 15.4)

8.90

(8.43, 8.95)

0.118

(0.070, 0.118)

3 + 3

T2

11.1

(11.1, 11.1)

2.59

(2.59, 2.63)

23.2

(23.2, 24.2)

10.95

(10.95, 11.17)

19.7

(19.7, 20.7)

16.05

(16.05, 16.31)

0.127

(0.127, 0.144)

STARPAC

T3

13.2

(13.0, 13.7)

2.74

(2.68, 2.90)

17.1

(17.1, 17.4)

3.86

(3.82, 4.11)

13.9

(13.9, 14.8)

7.87

(7.87, 8.38)

0.468

(0.441, 0.506)

TITE-CRM

T3

13.0

(12.7, 13.2)

2.88

(2.85, 3.02)

17.0

(16.3, 17.0)

3.87

(3.71, 3.87)

14.0

(13.7, 14.1)

8.00

(7.90, 8.12)

0.637

(0.637, 0.708)

3 + 3

T3

11.9

(11.9, 12.2)

2.39

(2.39, 2.43)

25.3

(25.3, 27.1)

12.18

(12.18, 12.67)

21.6

(21.6, 23.2)

17.93

(17.93, 18.75)

0.165

(0.141, 0.168)

STARPAC

T4

15.0

(14.7, 15.6)

2.23

(2.16, 2.37)

19.5

(19.4, 19.7)

4.60

(4.58, 4.64)

15.8

(15.8, 16.8)

8.90

(8.90, 9.69)

0.728

(0.691, 0.776)

TITE-CRM

T4

11.4

(10.9, 11.6)

1.71

(1.63, 1.82)

14.6

(14.6, 15.0)

3.32

(3.19, 3.40)

12.3

(11.8, 12.5)

7.04

(6.59, 7.04)

0.895

(0.879, 0.932)

3 + 3

T4

13.2

(13.2, 13.4)

1.79

(1.78, 1.82)

29.2

(29.2, 29.9)

14.12

(14.12, 14.84)

24.9

(24.9, 25.7)

20.81

(20.81, 21.85)

0.456

(0.443, 0.473)

STARPAC

T5

12.8

(12.7, 13.3)

3.59

(3.54, 3.81)

16.5

(16.4, 17.0)

3.74

(3.74, 3.88)

13.7

(13.6, 14.2)

7.41

(7.41, 8.08)

0.444

(0.439, 0.476)

TITE-CRM

T5

16.6

(16.5, 17.0)

5.11

(5.11, 5.51)

21.6

(21.5, 22.3)

5.08

(4.92, 5.17)

18.2

(17.9, 18.6)

10.66

(10.44, 10.72)

0.347

(0.255, 0.347)

3 + 3

T5

9.9

(9.9, 10.1)

2.65

(2.65, 2.68)

20.4

(20.4, 21.7)

9.55

(9.55, 9.98)

17.3

(17.3, 18.7)

13.91

(13.91, 14.68)

0.349

(0.332, 0.349)